FindTrial
Sign In

PROPHYLACTIC, DOUBLE BLIND, PLACEBO CONTROLLED RANDOMIZED USE OF HOMEOPATHY FOR PREVENTION OF ATRIAL FIBRILLATION IN PATIENTS WITH AORTOCORONARY BYPASS OR HEART VALVE SURGERY WITH HEART-LUNG MACHINE - Prevention of atrial fibrillation

PROPHYLACTIC, DOUBLE BLIND, PLACEBO CONTROLLED RANDOMIZED USE OF HOMEOPATHY FOR PREVENTION OF ATRIAL FIBRILLATION IN PATIENTS WITH AORTOCORONARY BYPASS OR HEART VALVE SURGERY WITH HEART-LUNG MACHINE - Prevention of atrial fibrillation

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2008-002803-17-AT
Enrollment
238
Registered
2008-08-07
Start date
2008-09-04
Completion date
Unknown
Last updated
2020-02-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients suffering from atrial fibrillation following heart surgery

Interventions

Trade Name: Strychnos Nux vomica C200 Product Name: Strychnos Nux Vomica C200 Product Code: 1 Pharmaceutical Form: Sublingual tablet Pha

Sponsors

Med. Univ. Wien, Klinik Innere Medizin I, Intensivstation
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Planned heart surgery with heart-lung machine Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Age below 18 or beyond 100 years, pregnant patients

Design outcomes

Primary

MeasureTime frame
Main Objective: Strychnos Nux vomica prevents atrial fibrillation following heart surgery;Secondary Objective: Influence of Strychos Nux vomica on electrolytes;Primary end point(s): Observational period of 11 days—

Countries

Austria

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026